ReviewFrontiers in immunology2018

Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses.

Shin-Ichiro Fujii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.